Tysabri and PML: Understanding the Risk and Monitoring Guidelines

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational Exposure Concerns

If you or a loved one is taking Tysabri, the risk of progressive multifocal leukoencephalopathy (PML) can be a serious concern. Understanding who may need monitoring and the timeline of risk is essential for informed decision-making. This page provides a factual overview of PML risk factors, monitoring recommendations, and long-term outlook, building on decades of clinical experience with this therapy.

Find Out If You Qualify for Compensation →

Medical Background and Clinical Presentation of PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis (MS) and for Crohn's disease when other treatments are not appropriate. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. PML is an opportunistic viral infection of the brain caused by the JC virus, which typically only occurs in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The condition results from reactivation of latent JC virus, which then infects oligodendrocytes, leading to demyelination and progressive neurological deficits. Clinical presentation may include cognitive decline, motor weakness, visual disturbances, speech difficulties, and seizures. Diagnosis is confirmed through MRI imaging, cerebrospinal fluid analysis for JC virus DNA, and brain biopsy in ambiguous cases. Early recognition is critical because prompt intervention can influence outcomes, though prognosis remains poor, with most patients experiencing irreversible disability or death.

Tysabri Pharmacology and PML Risk Factors

Tysabri is a monoclonal antibody that binds to alpha-4 integrin, preventing immune cell migration into the central nervous system. While this mechanism reduces inflammatory activity in MS, it also impairs immune surveillance, creating an environment permissive for JC virus reactivation. The FDA-approved labeling includes a boxed warning stating that Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors for PML in Tysabri-treated patients are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy, weighing expected benefit against PML risk. Clinical trial data document PML occurrence in Tysabri recipients. In MS trials, two cases of PML were observed among 1869 patients treated for a median of 120 weeks; both patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). A third case occurred after eight doses in one of 1043 Crohn's disease patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases underscore that PML can develop even within the first two years of treatment, though risk increases with longer exposure.

Risk Management and Legal Considerations

Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals must monitor patients for any new signs or symptoms suggestive of PML and withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The labeling also advises that Tysabri should not be used in combination with immunosuppressants or TNF-alpha inhibitors in Crohn's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, PML continues to occur, raising questions about the adequacy of risk communication and patient monitoring. For patients who develop PML after Tysabri exposure, legal claims may focus on whether the manufacturer provided adequate warnings about PML risk. The boxed warning explicitly states that Tysabri increases PML risk and identifies known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, plaintiffs may argue that warnings were insufficient regarding the magnitude of risk, the need for more frequent monitoring, or the limitations of risk stratification tools. Attorney-related considerations include establishing a clear timeline between Tysabri exposure and PML diagnosis, documenting that the patient met risk factor criteria (e.g., anti-JCV antibody positivity, prior immunosuppressant use), and demonstrating that PML caused specific harms such as disability or death. Settlement criteria often depend on the strength of evidence linking Tysabri to the patient's PML, the severity of injury, and whether the manufacturer's warnings were deemed adequate by regulatory standards.

Timeline Between Exposure and Harm

The latency between Tysabri initiation and PML onset varies. In clinical trials, PML occurred after a median of 120 weeks in MS patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing data indicate that risk increases with treatment duration, particularly beyond two years. For legal purposes, establishing a temporal relationship requires medical records documenting Tysabri administration dates, PML symptom onset, and diagnostic confirmation. The latency period can complicate causation analysis, but the known biological mechanism and epidemiological evidence support a causal link.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is Tysabri and why is it associated with PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus, due to its mechanism of blocking immune cell migration into the central nervous system.

What are the key risk factors for developing PML while on Tysabri?

The three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be assessed before and during therapy.

What legal considerations exist for Tysabri-associated PML lawsuits?

Legal claims often focus on whether the manufacturer provided adequate warnings about PML risk. Key elements include establishing a clear timeline of exposure and diagnosis, documenting risk factors, and demonstrating that PML caused specific harms. Settlement criteria depend on evidence strength, injury severity, and warning adequacy.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed - Tysabri Labeling

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.